Photocure ASA: Results for the fourth quarter of 2024
Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 128.6 million in the fourth quarter of 2024 (Q4 2023: NOK ...
Medindia4 天
Bladder Cancer: Upstaging and risk mitigation with Blue Light Cystoscopy in NMIBC featured ...
The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S. bladder cancer patient registry at the 2025 Genitourinary Cancers Symposium ...
Photocure: Bladder Cancer: Upstaging and risk mitigation with Blue Light Cystoscopy in ...
The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S.